Trial Profile
A Six Month, Randomized, Open-Label, Safety Study of Symbicort [budesonide/formoterol] (160/4.5microg) Compared to Pulmicort Turbuhaler in Asthmatic Children Aged Six to Eleven Years - SAPLING
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2010
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAPLING
- Sponsors AstraZeneca
- 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
- 13 Jun 2008 New trial record.